Loading
The combination of gemcitabine and docetaxel produced responses in more than half of patients with leiomyosarcoma, most of them uterine and many previously treated with doxorubicin, establishing a widely used second regimen for the disease.
Phase 2 study of 34 patients with unresectable leiomyosarcoma (29 uterine) treated with fixed-dose-rate gemcitabine followed by docetaxel every three weeks with growth factor support.
Objective response was 53 percent including three complete responses, with responses in patients previously treated with doxorubicin; median time to progression was 5.6 months and myelosuppression was the main toxicity.
Gemcitabine-docetaxel is a standard first- or second-line option for leiomyosarcoma, especially uterine, and remains in use alongside doxorubicin-based regimens.
Shares Docetaxel, Gemcitabine.
Shares Docetaxel, Journal of Clinical Oncology.
Shares Docetaxel, Gemcitabine.
Shares Docetaxel, Gemcitabine.
Shares Docetaxel, Gemcitabine.
Shares Docetaxel, Gemcitabine.
Shares Docetaxel, Gemcitabine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/